Telix Investors Urged to Seek Lead‑Plaintiff Role by Jan. 9 in Securities Class Action

The case turns on two 2025 regulatory disclosures that preceded sharp ADS losses.

Overview

New notices from Hagens Berman, Faruqi & Faruqi, and Rosen call on Telix ADS purchasers to contact counsel and move for lead-plaintiff appointment by January 9, 2026.
The filed complaint alleges Telix overstated progress on prostate-cancer candidates TLX591 and TLX592 and overstated the quality of third-party manufacturing and supply partners.
On July 22, 2025, Telix disclosed an SEC subpoena seeking information about its prostate-therapy disclosures, after which ADSs fell more than 13% over two trading sessions.
On August 28, 2025, Telix reported an FDA Complete Response Letter for TLX250-CDx citing CMC deficiencies and Form 483 observations at two external manufacturers, and ADSs fell more than 21% over two sessions.
A class action has been filed but no class has been certified, and investors may either seek a leadership role or remain absent class members.